McClellan William D. Jr.'s Form 4 filing
Reata Pharmaceuticals Inc (RETA) · filed Aug 1, 2023
- Accession no.
- 0001209191-23-043997
- Filed
- Aug 1, 2023
- Trade date
- Jul 28, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $822.5K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McClellan William D. Jr.CIK 0001689402 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 28, 2023 | Class A common stock | CConversionAcquired | +5,000 | – | – | 11,017 | Direct | |
| Jul 28, 2023 | Class A common stock | SSaleDisposed | −5,000 | $164.49 | −$822,450 | 6,017 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 28, 2023 | Class B common stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 4,500 | Direct | |
| Jul 28, 2023 | Class A common stock | MOption exerciseAcquired | +5,000 | $26.46 | +$132,300 | 5,000 | Direct | |
| Jul 28, 2023 | Class A common stock | CConversionDisposed | −5,000 | – | – | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.